Page 2 - Peter Lio News Today

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

Scientists say climate change issues such as global warming can exacerbate the symptoms of atopic dermatitis, a skin condition also known as eczema

Lisa Swanson, MD, PhD, highlights dermatology biologics coordinators as a resource for getting better access to JAK inhibitors.

Dermatology experts discuss the use of JAK inhibitors in clinical practice, highlighting their own experiences and use of JAKs alongside corticosteroids.

Expert dermatologists share clinical pearls for providers treating patients with AD, and discuss the future of AD treatment.

Peter Lio, MD, reviews the contraindications of JAK inhibitors in AD and approaches for monitoring patients who are prescribed a JAK inhibitor.

Expert dermatologists speak on shared-decision making between the patient and the provider when it comes to selecting the right therapy for AD.

Researchers say skin diseases such as atopic dermatitis can cause itching and other effects that disturb a person's sleep